Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H9I3N2O4.C7H17NO5 |
Molecular Weight | 809.1272 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=MIKKOBKEXMRYFQ-WZTVWXICSA-N
InChI=1S/C11H9I3N2O4.C7H17NO5/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2H3,(H,15,17)(H,16,18)(H,19,20);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
DescriptionSources: http://www.drugbank.ca/drugs/DB00271Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00271
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=3198373
Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Cystografin Approved UseRetrograde cystourethrography Launch Date1955 |
|||
Diagnostic | Gastrografin Approved UseGastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.6 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Transcervical catheterization and cervical patency during the oestrous cycle in domestic cats. | 2001 |
|
The accordion sign at CT: report of a case of Crohn's disease with diffuse colonic involvement. | 2001 |
|
Spontaneous pneumomediastinum. | 2001 Apr |
|
Preoperative bowel preparation with meglumine and sodium diatrizoate (Gastrografin): a prospective randomised comparison. | 2001 Dec |
|
Results after colectomy for colonic inertia: a sixteen-year experience. | 2001 Dec |
|
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. | 2001 Dec |
|
[Nephrotoxicity of X-ray contrast media]. | 2001 Jan-Feb |
|
Add-on angiotensin receptor blockade with maximized ACE inhibition. | 2001 Jun |
|
Effect of ionic and nonionic contrast media on fibrinolysis in patients undergoing angiocardiography. | 2001 Oct |
|
[Opportunities of delayed densitometry of "late (fixed) contrast" as a test for tumors in residual mediastinal lesion in primary mediastinal lymphosarcoma after polychemotherapy]. | 2002 |
|
Electrocardiographic effects of diagnostic imaging agents. | 2002 Aug |
|
Primary anastomosis and diverting colostomy in diffuse diverticular peritonitis. | 2002 Feb |
|
The utility of contrast studies and drains in the management of patients after Roux-en-Y gastric bypass. | 2002 Feb |
|
Plasma exogenous creatinine clearance test in dogs: comparison with other methods and proposed limited sampling strategy. | 2002 Jan-Feb |
|
Iodinated contrast medium-induced potassium release: the effect of mixing ratios. | 2002 Jul-Aug |
|
Role of NO in endothelin-regulated drug transport in the renal proximal tubule. | 2002 Mar |
|
Pressure-assisted micturating cystourethrography: reduction in duration of procedure and fluoroscopy time. | 2002 Nov |
|
The value of contrast radiology for postoperative adhesive small bowel obstruction. | 2002 Nov-Dec |
|
Venous port salvage utilizing low dose tPA. | 2002 Nov-Dec |
|
Chronic renal dysfunction late after liver transplantation. | 2002 Oct |
|
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model. | 2002 Sep |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html
;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
||
|
CFR |
21 CFR 522.563
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000091437
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
131-49-7
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
31812
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201220
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
DTXSID20897171
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
m4263
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | Merck Index | ||
|
205-024-7
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
53692
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
4208
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
3X9MR4N98U
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
SUB03119MIG
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
3X9MR4N98U
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
DBSALT000844
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
8566
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
C29247
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
D003974
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | |||
|
3320
Created by
admin on Fri Dec 15 15:16:15 GMT 2023 , Edited by admin on Fri Dec 15 15:16:15 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD